- Home
- IPSC
as 07-26-2024 4:00pm EST
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | PHILADELPHIA |
| Market Cap: | 199.4M | IPO Year: | 2021 |
| Target Price: | $14.17 | AVG Volume (30 days): | 371.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.21 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.28 - $5.51 | Next Earning Date: | 08-07-2024 |
| Revenue: | $1,370,000 | Revenue Growth: | -76.63% |
| Revenue Growth (this year): | 271.41% | Revenue Growth (next year): | 68.71% |
Stock Insider Trading Activity of Century Therapeutics Inc. (IPSC)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Russotti Gregory | IPSC | See Remarks | Jun 20 '24 | Sell | $2.84 | 5,000 | $14,178.50 | 277,319 | SEC Form 4 |
| Russotti Gregory | IPSC | See Remarks | Jun 5 '24 | Sell | $3.00 | 5,000 | $14,989.00 | 282,319 | SEC Form 4 |
| Russotti Gregory | IPSC | See Remarks | May 20 '24 | Sell | $3.00 | 5,000 | $14,977.50 | 287,319 | SEC Form 4 |
| Russotti Gregory | IPSC | See Remarks | May 6 '24 | Sell | $3.12 | 5,000 | $15,619.00 | 292,319 | SEC Form 4 |
| Farid Adrienne | IPSC | Chief Operations Officer | May 3 '24 | Sell | $3.11 | 913 | $2,835.78 | 137,236 | SEC Form 4 |
| Carr Douglas | IPSC | SVP Finance & Operations | May 3 '24 | Sell | $3.11 | 257 | $798.24 | 317,323 | SEC Form 4 |
| Russotti Gregory | IPSC | See Remarks | Apr 22 '24 | Sell | $3.10 | 5,000 | $15,489.50 | 297,319 | SEC Form 4 |
| Farid Adrienne | IPSC | Chief Operations Officer | Mar 6 '24 | Sell | $5.14 | 22,831 | $117,342.21 | 114,149 | SEC Form 4 |
| Farid Adrienne | IPSC | Chief Operations Officer | Mar 6 '24 | Sell | $4.96 | 30,684 | $152,339.92 | 114,149 | SEC Form 4 |
| Farid Adrienne | IPSC | Chief Operations Officer | Feb 16 '24 | Sell | $4.86 | 485 | $2,358.26 | 114,149 | SEC Form 4 |
| Carr Douglas | IPSC | SVP Finance & Operations | Feb 5 '24 | Sell | $4.49 | 557 | $2,499.26 | 303,580 | SEC Form 4 |
| Carr Douglas | IPSC | SVP Finance & Operations | Feb 5 '24 | Sell | $3.84 | 643 | $2,469.76 | 304,137 | SEC Form 4 |
| Farid Adrienne | IPSC | Chief Operations Officer | Feb 5 '24 | Sell | $3.84 | 2,035 | $7,816.44 | 115,933 | SEC Form 4 |
| Farid Adrienne | IPSC | Chief Operations Officer | Feb 5 '24 | Sell | $4.49 | 1,784 | $8,004.81 | 114,149 | SEC Form 4 |
Latest Century Therapeutics Inc. News
IPSC Breaking Stock News: Dive into IPSC Ticker-Specific Updates for Smart Investing
Simply Wall St.
14 days ago
After losing 17% in the past year, Century Therapeutics, Inc. (NASDAQ:IPSC) institutional owners must be relieved by the recent gain
Zacks
17 days ago
Century Therapeutics (IPSC) Moves to Buy: Rationale Behind the Upgrade
MT Newswires
a month ago
Century Therapeutics Proposes Secondary Offering of 7.87 Million Shares
MT Newswires
a month ago
Piper Sandler Adjusts Price Target on Century Therapeutics to $12 From $9, Maintains Overweight Rating
GlobeNewswire
2 months ago
Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting
GuruFocus.com
3 months ago
Century Therapeutics Inc (IPSC) Q1 2024 Earnings: Aligns with EPS Projections Amid Strategic ...
GlobeNewswire
3 months ago
Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting
Zacks
3 months ago
Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Tops Revenue Estimates
Compare IPSC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IPSC Century Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.